AU2021276614A1 - Treatment for viral respiratory infections - Google Patents

Treatment for viral respiratory infections Download PDF

Info

Publication number
AU2021276614A1
AU2021276614A1 AU2021276614A AU2021276614A AU2021276614A1 AU 2021276614 A1 AU2021276614 A1 AU 2021276614A1 AU 2021276614 A AU2021276614 A AU 2021276614A AU 2021276614 A AU2021276614 A AU 2021276614A AU 2021276614 A1 AU2021276614 A1 AU 2021276614A1
Authority
AU
Australia
Prior art keywords
antagonist
subject
cells
antibody
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021276614A
Other languages
English (en)
Inventor
Syed Muhammad Tahir NASSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosirius Ltd
Original Assignee
Biosirius Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosirius Ltd filed Critical Biosirius Ltd
Publication of AU2021276614A1 publication Critical patent/AU2021276614A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021276614A 2020-05-19 2021-05-19 Treatment for viral respiratory infections Pending AU2021276614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007404.3 2020-05-19
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Publications (1)

Publication Number Publication Date
AU2021276614A1 true AU2021276614A1 (en) 2023-01-05

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021276614A Pending AU2021276614A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Country Status (12)

Country Link
US (1) US20230192838A1 (https=)
EP (1) EP4153302B1 (https=)
JP (1) JP2023526853A (https=)
KR (1) KR20230053549A (https=)
CN (1) CN116406289A (https=)
AU (1) AU2021276614A1 (https=)
CA (1) CA3179461A1 (https=)
ES (1) ES2982939T3 (https=)
GB (1) GB202007404D0 (https=)
HU (1) HUE067327T2 (https=)
PL (1) PL4153302T3 (https=)
WO (1) WO2021234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
MX2013007067A (es) * 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US20230173021A1 (en) * 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases

Also Published As

Publication number Publication date
CN116406289A (zh) 2023-07-07
HUE067327T2 (hu) 2024-10-28
JP2023526853A (ja) 2023-06-23
GB202007404D0 (en) 2020-07-01
WO2021234381A1 (en) 2021-11-25
PL4153302T3 (pl) 2024-10-07
US20230192838A1 (en) 2023-06-22
EP4153302A1 (en) 2023-03-29
EP4153302B1 (en) 2024-05-29
EP4153302C0 (en) 2024-05-29
CA3179461A1 (en) 2021-11-25
ES2982939T3 (es) 2024-10-21
KR20230053549A (ko) 2023-04-21

Similar Documents

Publication Publication Date Title
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
WO2021202563A1 (en) Methods of treating coronavirus infection
US20120148532A1 (en) Method of treating pulmonary disease with interferons
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
EP4153302B1 (en) Treatment for viral respiratory infections
CN102548573A (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
WO2023067348A1 (en) Treatment for virally-induced pneumonia
JP2023518814A (ja) Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
CN115209914A (zh) 用干扰素λ治疗冠状病毒感染
McGill et al. Interleukin-5 inhibition of biliary cell chloride currents and bile flow
US20230365712A1 (en) Notch4 antibodies and uses thereof
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
WO2014060210A1 (en) Methods and compositions for the treatment of pancreatic cancer
EP4107186A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
JP6882440B2 (ja) 抗ｉｌ４−ｉｌ１３二重特異性抗体
KR20010024549A (ko) Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도
EP2494982B1 (en) Method of treating pulmonary disease with interferons
US8105571B2 (en) Method of treating pulmonary disease with interferons
US20220403036A1 (en) P-selectin inhibitor, compositions thereof and methods of use thereof
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
Protocol Protocol Title: Effect of Interferon-gamma 1-b (IFN-γ lb) on Innate Immune Cells